Neuroproteomics: Expression Profiling of the Brain's Proteomes in Health and Disease

The term “proteome” describes the protein complement of a genome. Proteomes of cells are dynamic and are directly affected by environmental factors, such as stress and/or drug treatment, or as a result of aging and disease. One of the distinct advantages of proteomic analysis, not attainable with RNA expression data, is the ability to fractionate the cell's proteins into various subpopulations. In neuroscience, “neuromics” (proteomics in the central nervous system) is in its infancy, with a paucity of studies in the context of the brain. One of the objectives of this review is to illustrate the potential of neuromics to profile differences in the distribution of thousands of proteins as a function of disease markers. We have previously used this approach to determine the effects of varied postmortem interval in examining human brain tissue and to identify biomarkers. Here we review proteomic studies of schizophrenia, Alzheimer's disease, and Parkinson's disease. Experimental results regarding Parkinson's disease are presented to illustrate the potential of neuromics to identify pathways of pathogenesis and novel therapeutic targets.

[1]  S. Gygi,et al.  Correlation between Protein and mRNA Abundance in Yeast , 1999, Molecular and Cellular Biology.

[2]  J. Coyle,et al.  Glutamatergic mechanisms in schizophrenia. , 2003, Annual review of pharmacology and toxicology.

[3]  R. Aebersold,et al.  Advances in proteome analysis by mass spectrometry. , 2001, The Journal of biological chemistry.

[4]  B. Giasson,et al.  Effects of Oxidative and Nitrative Challenges on α-Synuclein Fibrillogenesis Involve Distinct Mechanisms of Protein Modifications* , 2003, Journal of Biological Chemistry.

[5]  W. Nicklas,et al.  Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1985, Life sciences.

[6]  B. Cravatt,et al.  Activity-based protein profiling: the serine hydrolases. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[7]  E. Tolosa,et al.  Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson's disease. , 1993, Neurology.

[8]  Steven W. Taylor,et al.  Global organellar proteomics. , 2003, Trends in biotechnology.

[9]  A. Lees,et al.  A Generalised Increase in Protein Carbonyls in the Brain in Parkinson's but Not Incidental Lewy Body Disease , 1997, Journal of neurochemistry.

[10]  R. Wyatt,et al.  Cerebrospinal fluid protein variations in common to Alzheimer's disease and schizophrenia. , 1992, Applied and theoretical electrophoresis : the official journal of the International Electrophoresis Society.

[11]  L. Liotta,et al.  Laser capture microdissection. , 2006, Methods in molecular biology.

[12]  N. Hattori,et al.  Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[13]  M. Kennedy,et al.  Identification of Proteins in the Postsynaptic Density Fraction by Mass Spectrometry , 2000, The Journal of Neuroscience.

[14]  Howard B Gutstein,et al.  Navigated laser capture microdissection as an alternative to direct histological staining for proteomic analysis of brain samples , 2003, Proteomics.

[15]  R. Malinow,et al.  APP Processing and Synaptic Function , 2003, Neuron.

[16]  M. Webster,et al.  Application of cDNA microarrays to examine gene expression differences in schizophrenia , 2001, Brain Research Bulletin.

[17]  D. Lewis,et al.  Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia , 2001, Molecular Psychiatry.

[18]  A. C. Collins,et al.  The Role of RNA Editing of Kainate Receptors in Synaptic Plasticity and Seizures , 2001, Neuron.

[19]  B. Gerrits,et al.  Preparative two‐dimensional gel electrophoresis at alkaline pH using narrow range immobilized pH gradients , 2002, Proteomics.

[20]  C. Marsden,et al.  Mitochondrial Complex I Deficiency in Parkinson's Disease , 1990, Lancet.

[21]  R. Tjian,et al.  Transcription regulation and animal diversity , 2003, Nature.

[22]  C. Marín,et al.  Mitochondria1 respiratory chain activity in skeletal muscle from patients with Parkinson's disease , 1993, Neurology.

[23]  L. Elferink,et al.  Tyrosine Hydroxylase Is Inactivated by Catechol‐Quinones and Converted to a Redox‐Cycling Quinoprotein , 1999, Journal of neurochemistry.

[24]  C. Yip,et al.  Amyloid-beta peptide assembly: a critical step in fibrillogenesis and membrane disruption. , 2001, Biophysical journal.

[25]  Todd B. Sherer,et al.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.

[26]  Robert Hill,et al.  Low platelet mitochondrial complex I and complex II/III activity in early untreated parkinson's disease , 1995, Annals of neurology.

[27]  G. Evin,et al.  Biogenesis and metabolism of Alzheimer’s disease Aβ amyloid peptides , 2002, Peptides.

[28]  S. Weinberger,et al.  Recent trends in protein biochip technology. , 2000, Pharmacogenomics.

[29]  M. Mann,et al.  4. Proteomic Analysis of Posttranslational Modifications , 2013 .

[30]  M. Zigmond,et al.  Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[31]  C. Haass,et al.  Neurotoxic Mechanisms Caused by the Alzheimer's Disease-linked Swedish Amyloid Precursor Protein Mutation , 2003, Journal of Biological Chemistry.

[32]  Pat Levitt,et al.  Analysis of complex brain disorders with gene expression microarrays: schizophrenia as a disease of the synapse , 2001, Trends in Neurosciences.

[33]  Kai Stühler,et al.  Genetic analysis of the mouse brain proteome , 2002, Nature Genetics.

[34]  C D Marsden,et al.  Oxidative DNA Damage in the Parkinsonian Brain: An Apparent Selective Increase in 8‐Hydroxyguanine Levels in Substantia Nigra , 1997, Journal of neurochemistry.

[35]  Richard D. Smith,et al.  Proteome analysis by mass spectrometry. , 2003, Annual review of biophysics and biomolecular structure.

[36]  E. Floor,et al.  Increased Protein Oxidation in Human Substantia Nigra Pars Compacta in Comparison with Basal Ganglia and Prefrontal Cortex Measured with an Improved Dinitrophenylhydrazine Assay , 1998, Journal of neurochemistry.

[37]  I. Kanazawa,et al.  Reduction of GluR2 RNA editing, a molecular change that increases calcium influx through AMPA receptors, selective in the spinal ventral gray of patients with amyotrophic lateral sclerosis , 1999, Annals of neurology.

[38]  M. Steinmetz,et al.  Isotope-tagged cross-linking reagents. A new tool in mass spectrometric protein interaction analysis. , 2001, Analytical chemistry.

[39]  Joachim Klose,et al.  Alterations in the Mouse and Human Proteome Caused by Huntington’s Disease* , 2002, Molecular & Cellular Proteomics.

[40]  M. Stoeckli,et al.  Imaging mass spectrometry: A new technology for the analysis of protein expression in mammalian tissues , 2001, Nature Medicine.

[41]  P. R. Gardner,et al.  Superoxide Radical and Iron Modulate Aconitase Activity in Mammalian Cells (*) , 1995, The Journal of Biological Chemistry.

[42]  D. Beher,et al.  Generation of C-terminally truncated amyloid-beta peptides is dependent on gamma-secretase activity. , 2002, Journal of neurochemistry.

[43]  J. B. Justice,et al.  Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter , 2001, Journal of neurochemistry.

[44]  J. Seilhamer,et al.  A comparison of selected mRNA and protein abundances in human liver , 1997, Electrophoresis.

[45]  R. Faull,et al.  Proteomic analysis of the brain in Alzheimer’s disease: Molecular phenotype of a complex disease process , 2001, Proteomics.

[46]  C. Marsden,et al.  Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease , 2005, Journal of Neural Transmission.

[47]  R. Aebersold,et al.  Mass spectrometry-based proteomics , 2003, Nature.

[48]  Jacob Raber,et al.  Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[49]  M. Vingron,et al.  Improved sensitivity proteomics by postharvest alkylation and radioactive labeling of proteins , 2000, Electrophoresis.

[50]  F. Gage,et al.  Neprilysin Gene Transfer Reduces Human Amyloid Pathology in Transgenic Mice , 2003, The Journal of Neuroscience.

[51]  T. Montine,et al.  Covalent Crosslinking of Neurofilament Proteins by Oxidized Catechols as a Potential Mechanism of Lewy Body Formation , 1995, Journal of neuropathology and experimental neurology.

[52]  T. Hastings,et al.  Role of oxidative changes in the degeneration of dopamine terminals after injection of neurotoxic levels of dopamine , 2000, Neuroscience.

[53]  M. Mann,et al.  Directed Proteomic Analysis of the Human Nucleolus , 2002, Current Biology.

[54]  S. Fields,et al.  Protein analysis on a proteomic scale , 2003, Nature.

[55]  M. Zigmond,et al.  Identification of Catechol‐Protein Conjugates in Neostriatal Slices Incubated with [3H]Dopamine: Impact of Ascorbic Acid and Glutathione , 1994, Journal of neurochemistry.

[56]  C. Moraes,et al.  Titrating the Effects of Mitochondrial Complex I Impairment in the Cell Physiology* , 1999, The Journal of Biological Chemistry.

[57]  D. Beher,et al.  Generation of C‐terminally truncated amyloid‐β peptides is dependent on γ‐secretase activity , 2002 .

[58]  A. Murphy,et al.  Complex I-mediated reactive oxygen species generation: modulation by cytochrome c and NAD(P)+ oxidation-reduction state. , 2002, The Biochemical journal.

[59]  L. Bianchi,et al.  Complexities in the neurotoxic actions of 6-hydroxydopamine in relation to the cytoprotective properties of taurine , 2001, Brain Research Bulletin.

[60]  Susumu Tonegawa,et al.  Dopamine D2 Long Receptor-Deficient Mice Display Alterations in Striatum-Dependent Functions , 2000, The Journal of Neuroscience.

[61]  S. Hoving,et al.  Towards high performance two‐dimensional gel electrophoresis using ultrazoom gels , 2000, Electrophoresis.

[62]  M. Wilkins,et al.  Progress with gene‐product mapping of the Mollicutes: Mycoplasma genitalium , 1995, Electrophoresis.

[63]  K. Henke,et al.  Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease , 2003, Neuron.

[64]  Timothy B. Stockwell,et al.  The Sequence of the Human Genome , 2001, Science.

[65]  B. Giasson,et al.  Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. , 2000, The Journal of biological chemistry.

[66]  P. Bork,et al.  Functional organization of the yeast proteome by systematic analysis of protein complexes , 2002, Nature.

[67]  K. Henke,et al.  Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. , 2003, Neuron.

[68]  C. Fall,et al.  Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. , 1997, Biochimica et biophysica acta.

[69]  Michael S. Wolfe,et al.  γ-Secretase is a membrane protein complex comprised of presenilin, nicastrin, aph-1, and pen-2 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[70]  K. Blennow,et al.  Comparative genome‐ and proteome analysis of cerebral cortex from MK‐801‐treated rats , 2003, Journal of neuroscience research.

[71]  B. Cravatt,et al.  Profiling serine hydrolase activities in complex proteomes. , 2001, Biochemistry.

[72]  P. Selby,et al.  Laser capture microdissection and two-dimensional polyacrylamide gel electrophoresis: evaluation of tissue preparation and sample limitations. , 2002, The American journal of pathology.

[73]  P. Seeman,et al.  Schizophrenia: elevated mRNA for dopamine D2(Longer) receptors in frontal cortex. , 2001, Brain research. Molecular brain research.

[74]  M. Ünlü,et al.  Difference gel electrophoresis. A single gel method for detecting changes in protein extracts , 1997, Electrophoresis.

[75]  B. Halliwell,et al.  Free radicals in biology and medicine , 1985 .

[76]  D. Graham,et al.  Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. , 1978, Molecular pharmacology.

[77]  M. Kawahara,et al.  Molecular mechanism of neurodegeneration induced by Alzheimer’s β-amyloid protein: channel formation and disruption of calcium homeostasis , 2000, Brain Research Bulletin.

[78]  S. Grant,et al.  Proteomic analysis of NMDA receptor–adhesion protein signaling complexes , 2000, Nature Neuroscience.

[79]  I. Reynolds,et al.  DeltaPsi(m)-Dependent and -independent production of reactive oxygen species by rat brain mitochondria. , 2001, Journal of neurochemistry.

[80]  I. Sponne,et al.  Apoptotic Neuronal Cell Death Induced by the Non-fibrillar Amyloid-β Peptide Proceeds through an Early Reactive Oxygen Species-dependent Cytoskeleton Perturbation* , 2003, The Journal of Biological Chemistry.

[81]  Pat Levitt,et al.  Molecular Characterization of Schizophrenia Viewed by Microarray Analysis of Gene Expression in Prefrontal Cortex , 2000, Neuron.

[82]  R. Faull,et al.  A comparative proteome analysis of hippocampal tissue from schizophrenic and Alzheimer's disease individuals , 1999, Molecular Psychiatry.

[83]  C. Marsden,et al.  Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease , 1989, Journal of neurochemistry.

[84]  Wei Wu,et al.  Human cerebrospinal fluid protein database: Edition 1992 , 1992, Electrophoresis.

[85]  J. Choudhary,et al.  Interrogating the human genome using uninterpreted mass spectrometry data , 2001, Proteomics.

[86]  Dong-Kug Choi,et al.  Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[87]  A. Lees,et al.  Conjugates of Catecholamines with Cysteine and GSH in Parkinson's Disease: Possible Mechanisms of Formation Involving Reactive Oxygen Species , 1998, Journal of neurochemistry.

[88]  C. V. van Duijn,et al.  Parkinson's disease: piecing together a genetic jigsaw. , 2003, Brain : a journal of neurology.

[89]  S. Gygi,et al.  Quantitative analysis of complex protein mixtures using isotope-coded affinity tags , 1999, Nature Biotechnology.

[90]  R. Faull,et al.  Proteome map of the human hippocampus , 1999, Hippocampus.

[91]  M. Glucksman,et al.  Proteomics in the discovery of new therapeutic targets for psychiatric disease. , 2003, Current molecular medicine.

[92]  R. Faull,et al.  Comparative proteome analysis of the hippocampus implicates chromosome 6q in schizophrenia , 2000, Molecular Psychiatry.

[93]  F. Benes,et al.  Emerging principles of altered neural circuitry in schizophrenia , 2000, Brain Research Reviews.

[94]  Gary D Bader,et al.  Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry , 2002, Nature.

[95]  M. LaVoie,et al.  Dopamine Quinone Formation and Protein Modification Associated with the Striatal Neurotoxicity of Methamphetamine: Evidence against a Role for Extracellular Dopamine , 1999, The Journal of Neuroscience.

[96]  M. Zigmond,et al.  Modification of Dopamine Transporter Function: Effect of Reactive Oxygen Species and Dopamine , 1996, Journal of neurochemistry.

[97]  Richard M Caprioli,et al.  Imaging mass spectrometry: a new tool to investigate the spatial organization of peptides and proteins in mammalian tissue sections. , 2002, Current opinion in chemical biology.

[98]  Ian J. Reynolds,et al.  ΔΨm‐Dependent and ‐independent production of reactive oxygen species by rat brain mitochondria , 2001 .

[99]  B. Graveley.  Alternative splicing: increasing diversity in the proteomic world. , 2001, Trends in genetics : TIG.

[100]  Tadashi Kondo,et al.  Application of sensitive fluorescent dyes in linkage of laser microdissection and two‐dimensional gel electrophoresis as a cancer proteomic study tool , 2003, Proteomics.

[101]  V. Lee,et al.  Are Ubiquitination Pathways Central to Parkinson's Disease? , 2003, Cell.